Dr. Reddy's Laboratories Limited — Others, 09-05-2025: Change in Auditors

Dr. Reddy's Laboratories has announced a board meeting where it approved the financial results for the quarter and half-year. Consolidated revenues reached ₹8,506 Cr in Q4, up 20% YoY, and ₹32,554 Cr for FY25, up 17% YoY. Profit after tax increased 22% YoY to ₹1,594 Cr in Q4 and 2% YoY to ₹5,654 Cr for FY25, driven by growth in the Nicotine Replacement Therapy business and core segments like Global Generics. Gross margin dipped slightly due to price pressures and manufacturing leverage. The board approved a final dividend of ₹8 per share and re-appointed Mr. G V Prasad as Co-Chairman & Managing Director for five years. Makarand M. Joshi & Co. was appointed as Secretarial Auditors. Investigations into alleged anti-corruption issues remain unresolved, while geopolitical risks are monitored with expectations of full asset recoverability.